In prostate cancer, abrogating the expression of vimentin significantly decreases tumor cell invasiveness, an effect that has been attributed to its ability to regulate the E-cadherin/β-catenin complex via c-Src regulation [27]. Here, CDH1 is linked to prostate cancer.